Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-03-24 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
东海证券股份有限公司关于昆药集团股份有限公司2016年度之持续督导报告书
Audit Report / Information Classification · 95% confidence The document is titled as a "持续督导报告书" (Continuous Supervision Report) for the year 2016 by Donghai Securities for Kunming Pharmaceutical Group Co., Ltd. It references regulatory approvals, fundraising details, and the supervision activities conducted by the sponsor institution. The content focuses on the sponsor's ongoing supervision work, compliance with laws and regulations, review of information disclosure, and the use of raised funds. It does not contain full financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a regulatory compliance and supervision report related to the sponsor's duties under securities regulations. This type of document aligns best with the Audit Report / Information (AR) category, which includes standalone audit reports, applied accounting principles, and regulatory compliance reports excluding full annual reports. The document length (5464 characters) and detailed supervisory content support this classification with high confidence. FY 2016
2017-03-24 Chinese
中审众环关于昆药集团2016年内控审计报告
Regulatory Filings Classification · 90% confidence The document text contains only references to omitted pictures and a note about scanning software, with no substantive content, financial data, or report information. The document length is very short (246 characters), and there is no indication of any report or announcement content. Given the lack of any meaningful text or context, this document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2017-03-24 Chinese
东海证券股份有限公司关于昆药集团股份有限公司2016年度募集资金存放与实际使用情况专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Donghai Securities regarding the 2016 annual fundraising funds deposit and actual usage situation of Kunming Pharmaceutical Group Co., Ltd. It includes specific data on fundraising amounts, usage, account balances, compliance with regulatory requirements, and audit opinions. The document references regulatory guidelines related to fundraising management and includes tables showing the use of funds for specific projects. It is a specialized verification and audit report on the use of raised funds, not a general annual report or earnings release. The content aligns with an Audit Report / Information (AR) category, as it focuses on audit and verification of fundraising usage and compliance rather than full financial statements or management discussion. The document length (6764 characters) and detailed financial data support this classification rather than a brief announcement or regulatory filing. Therefore, the filing type is AR with high confidence. FY 2016
2017-03-24 Chinese
2016年度审计与风险委员会履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2016年度审计与风险委员会履职报告" which translates to the "2016 Annual Audit and Risk Committee Performance Report". It details the activities and meetings of the Audit and Risk Control Committee during 2016, including oversight of internal and external audits, review of financial reports, and audit plans. The document is a report on the committee's duties and audit supervision rather than the audit report itself or the full annual report. It does not contain full financial statements or detailed audit results but rather a summary of the committee's work and resolutions. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related information excluding full annual reports. The document length is 1876 characters, which is consistent with a committee report rather than a full annual report. Therefore, the appropriate classification is AR with high confidence. FY 2016
2017-03-24 Chinese
关于投资湖北易凯长江股权投资中心（有限合伙）的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding its investment of 30 million RMB into a private equity fund managed by Tianjin Yikai Tomorrow Asset Management Co., Ltd. The text details the fund's structure, management, investment strategy, risks, and the company's purpose for the investment. It is a formal disclosure about a capital investment transaction, not a financial report, earnings release, or management discussion. There is no indication of financial statements, audit information, or meeting materials. The document is a regulatory announcement about a financing/investment activity by the company, fitting the Capital/Financing Update category.
2017-03-24 Chinese
中审众环关于北京华方科泰医药有限公司2016年度业绩承诺完成情况专项审 核报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by a certified public accounting firm (中审众环会计师事务所) regarding the 2016 performance commitment completion status of Beijing Huafang Ketai Pharmaceutical Co., Ltd. It references the audit procedures, responsibilities of management, and the auditor's opinion on the fairness of the performance completion statement. The document includes financial figures related to net profit and compensation calculations tied to a share transfer agreement. It explicitly states it is a "专项审核报告" (special audit report) on the 2016 performance commitment completion, which is a standalone audit report rather than a full annual report or interim report. The document length is 3290 characters, which is relatively short but contains substantive audit content and financial data. It is not a mere announcement or certification letter but a detailed audit opinion on a specific matter. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2016
2017-03-24 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.